🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to researchers.

An International Challenge

The sexually transmitted infection are increasing worldwide, with estimates suggesting in excess of 82 million new cases annually. Particularly high rates are reported in Africa and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely development in the face of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options currently available.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". Ongoing monitoring found that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Secure Authorization

One new antibiotic, alternatively called a brand name, was authorized by the US FDA in December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Researchers anticipate that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, gained clearance in close succession. This drug, which is also used to treat UTIs, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to bring it to fruition.

“This approval signifies a major breakthrough in the therapy of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Testing Outcomes and Global Access

As per findings detailed in a prominent scientific publication, the new drug cured more than 90% of genital gonorrhoea infections. This places it at an equal footing with the existing first-line therapy, which involves an injection and a pill. The study involved hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the authority to license and sell the drug in many regions with limited resources.

Doctors treating patients have expressed positive views. Having a single-dose, oral treatment such as this is hailed as a "game-changer" for gonorrhoea control. This is deemed vital to lessen the impact of the disease for patients and to prevent the spread of extremely resistant gonorrhoea worldwide.